Evaxion A/S (EVGN) Filing Summary (Form 6-K/A)
This filing is an Amendment correcting the date of a prior announcement by the clinical-stage TechBio company.
- Material Event: Evaxion will announce its Business Update and Third Quarter 2025 Financial Results on November 6, 2025.
The announcement confirms the date for investor review of Q3 performance metrics.
Company Focus: AI-Immunology™ powered vaccines.
Regulatory: Registrant files under Form 20-F (Foreign Private Issuer).
Leadership: Report signed by Interim CEO, Birgitte Rønø.
Evaxion (EVAX) I